en · de · es · pt
melanotan-2-notes.peptides3626.com › Blog › Origins And Research Status — Field Notes

Origins And Research Status — Field Notes

By Editorial Desk · published 2026-03-30 · last reviewed 2026-05-13 · Blog

cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-05-13. Anything still debated is marked as such rather than presented as settled.

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Chemical Background and Receptor Activity

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideBelongs to the melanocortin agonist family
Key substitutionsNle4 and D-Phe7Improve resistance to enzymatic degradation
Molecular formulaC50H69N15O9Approximately 1024 g/mol
Regulatory statusNot approved as a medicineDistributed as a research chemical
Common synonymsMelanotan II, MT-II, MT-2Spelling varies across sources

Melanotan-2 Identity and Receptor Pharmacology

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Related pages on this site

Melanotan II Background and Mechanism

Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.

Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.

Supporting material

==== MeSH D12.776.964.950.800 – trans-activators ==== MeSH D12.776.964.950.800.385 – gene products, rev (HIV) MeSH D12.776.964.950.800.400 – gene products, tat MeSH D12.776.964.950.800.410 – gene products, tax MeSH D12.776.964.950.800.430 – gene products, vpr MeSH D12.776.964.950.800.445 – herpes simplex virus protein vmw65

== Medical uses == It has been proven to be effective in various inflammatory skin diseases, e.g., seborrheic dermatitis, cutaneous lupus erythematosus, oral lichen planus, vitiligo, and psoriasis. Tacrolimus and pimecrolimus are both calcineurin inhibitors and function as immunosuppressants.

Since the missile approached the target as it climbed, each of these intersections would be closer to the target. Taking several of these, in turn, the trajectory of the missile could be determined to some degree of accuracy, and air raid warnings sent to likely areas. Success in this task was aided by the missile fuselage profile, which acted as an excellent quarter-wave reflector for 12 m band HF radar. RAF Fighter Command was also informed of the launch in an effort to attack the sites. However, the German launch convoys were motorized, well camouflaged and highly mobile, making them extremely difficult to find and attack. The only known claim was made when Supermarine Spitfire pilots of No. 602 Squadron RAF squadron came across a V-2 rising from a wooded area, allowing a quick shot of unknown result.

Sources: en.wikipedia.org

Supporting material

A large number of important drugs exert their effects by interacting with norepinephrine systems in the brain or body. Their uses include treatment of cardiovascular problems, shock, and a variety of psychiatric conditions. These drugs are divided into: sympathomimetic drugs which mimic or enhance at least some of the effects of norepinephrine released by the sympathetic nervous system; sympatholytic drugs, in contrast, block at least some of the effects. Both of these are large groups with diverse uses, depending on exactly which effects are enhanced or blocked. Norepinephrine itself is classified as a sympathomimetic drug: its effects when given by intravenous injection of increasing heart rate and force and constricting blood vessels make it very useful for treating medical emergencies that involve critically low blood pressure. Surviving Sepsis Campaign recommended norepinephrine as first line agent in treating septic shock which is unresponsive to fluid resuscitation, supplemented by vasopressin and epinephrine. Dopamine usage is restricted only to highly selected patients.

== Biosynthesis == Papaverine is an isoquinoline alkaloid and the early steps in its biosynthesis from tyrosine are well established. The final step is known to be catalysed by the enzyme tetrahydroberberine oxidase, which oxidises (S)-tetrahydropapaverine:

The endothoracic fascia is the layer of loose connective tissue deep to the intercostal spaces and ribs, separating these structures from the underlying pleura. This fascial layer is the outermost membrane of the thoracic cavity. The endothoracic fascia contains variable amounts of fat. It becomes more fibrous over the apices of the lungs as the suprapleural membrane. It separates the internal thoracic artery from the parietal pleura.

Sources: en.wikipedia.org

Notes from published material

=== Sepsis === AM concentrations are substantially elevated during intense inflammation from disorders like sepsis, rendering AM a potentially viable therapeutic agent and clinical mode of monitoring such inflammation. AM contributes to vasodilation, which could be detrimental in leading to septic shock. Researchers seek to mitigate this effect while maintaining ADM's antimicrobial, anti-inflammatory, and endothelial-protective characteristics by employing antibodies that bind to ADM's N-terminus or co-administering ADM with ADM-binding protein-1, which collectively extend ADM's half-life and increase its maintenance role while minimizing this detrimental vasodilation. While AM has been discussed in regard to its implications for bacterial infections, such as sepsis, prior research explores its potential connection to viral infections too. This annunciates the importance of continual investigation into AM's mechanisms with viral illnesses through exploring its roles in inflammation and immune regulation.

=== Peptide === Ghrelin (Lenomorelin, GHRL) GHRP-1 GHRP-2 (Pralmorelin; GHRP Kaken 100; GHRP-2; KP-102, GPA-748, WAY-GPA-748) GHRP-3 GHRP-4 GHRP-5 GHRP-6 (SKF-110679) Alexamorelin Examorelin (hexarelin; EP-23905, MF-6003) Ipamorelin (NNC 26-0161) Relamorelin (RM-131, BIM-28131, BIM-28163) Tabimorelin (NN-703)

Bully: Garrett Height: Weight: Fighter: Jake Shields Height: 5'10 Weight: 170 lbs Victim(s): Kyle & Robert Money earned by Bully: $0 Money earned by victim(s): $10,000 Original airing: This episode was an online exclusive and was not aired on MTV in regular chronology with other episodes. It first aired on MTV2.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan II?

It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.

Is melanotan II an approved medicine?

No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.

What do published reports describe?

Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network